Keywords: boeh, ingel, enters, 265m, nanobody, deal, belgian
Boeh Ingel enters $265M Nanobody R&D deal
Article | 15 January 2007
Belgian biotechnology firm Ablynx NV has signed a deal worth over $265.0 million to allow privately-held German drug major Boehringer Ingelheim ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
